REFERENCES

• BenderDS.SkodolAE.Borderline personality as a self-other representational disturbance.J Personal Disord.200721500517
   PubMed Web of Science ®Google Scholar
• Choi-KainLW.GundersonJG.Mentalization: ontogeny, assessment, and application in the treatment of borderline personality disorder.Am J Psychiatry.20081651127113518676591
   PubMed Web of Science ®Google Scholar
• FonagyP.LuytenP.A developmental, mentalization-based approach to the understanding and treatment of borderline personality disorder.Dev Psychopathol.2009211355138119825272
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders. 4th Ed, Text Revision. Washington, DC: American Psychiatric Association;2000
   Google Scholar
• BlackDW.BlumN.PfohlB.HaleN.Suicidal behavior in borderline personality disorder: prevalence, risk factors, prediction, and prevention.J Personal Disord.200418226239
   PubMed Web of Science ®Google Scholar
• BrodskyBS.GrovesSA.OquendoMA.MannJJ.StanleyB.Interpersonal precipitants and suicide attempts in borderline personality disorder.Suicide Life Threat Behav.20063631332216805659
   PubMed Web of Science ®Google Scholar
• JovevM.JacksonHJ.The relationship between borderline personality disorder, life events, and functioning in an Australian psychiatric sample.J Personal Disord.200620205217
   PubMed Web of Science ®Google Scholar
• StiglmayrCE.Ebner-PriemerUW.BretzJ.et alDissociative symptoms are positively related to stress in borderline personality disorder.Acta Psychiatr Scand.200811713914718028248
   PubMed Web of Science ®Google Scholar
• GrantBF.ChouSP.GoldsteinRB.et alPrevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disordenresults from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions.J Clin Psychiatry.20086953354518426259
   PubMed Web of Science ®Google Scholar
• GrossR.OlfsonM.GameroffM.et alBorderline personality disorder in primary care.Arch Intern Med.2002162536011784220
   PubMed Web of Science ®Google Scholar
• SkodolA.GundersonJ.McGlashanT.et alFunctional Impairment in patients with schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders.Am J Psychiatry.200215927628311823271
   PubMed Web of Science ®Google Scholar
• LiebK.ZanariniMC.SchmahlC.LinehanMM.BohusM.Borderline personality disorder.Lancet.200436445346115288745
   PubMed Web of Science ®Google Scholar
• ZanariniMC.FrankenburgFR.KheraGS.BleichmarJ.Treatment histories of borderline inpatients.Compr Psychiatry.20014214415011244151
   PubMed Web of Science ®Google Scholar
• GundersonJG.Lyons-RuthK.BPD's interpersonal hypersensitivity phenotype:a gene-environment-developmental model.J Personal Disord.2008222241
   PubMed Web of Science ®Google Scholar
• JuddPH.Neurocognitive impairment as a moderator in the development of borderline personality disorder.Dev Psychopathol.2005171173119616613436
   PubMed Web of Science ®Google Scholar
• LuytenP.BlattSJ.Integrating theory-driven and empirically-derived models of personality development and psychopathology: a proposal for DSM-V.Clin Psychol Rev.201131526821130936
   PubMed Web of Science ®Google Scholar
• SteeleH.SieverU.An attachment perspective on borderline personality disorder:advances in gene-environment considerations.Curr Psychiatry Rep.201012616720425312
   PubMed Web of Science ®Google Scholar
• Choi-KainLW.ZanariniMC.FrankenburgFR.FitzmauriceGM.ReichDB.A longitudinal study of the 10-year course of interpersonal features in borderline personality disorder.J Personal Disord.201024365376
   PubMed Web of Science ®Google Scholar
• ZanariniMC.FrankenburgFR.ReichDB.SilkKR.HudsonJl.McSweeneyLB.The subsyndromal phenomenology of borderline personality disorders 10-year follow-up study.Am J Psychiatry.200716492993517541053
   PubMed Web of Science ®Google Scholar
• ZanariniMC.FrankenburgFR.ReichDB.FitzmauriceG.The 10-year course of psychosocial functioning among patients with borderline personality disorder and axis II comparison subjects.Acta Psychiatr Scand.201012210310920199493
   PubMed Web of Science ®Google Scholar
• GundersonJG.StoutRL.McGlashanTH.et alTen-year course of borderline personality disorder: psychopathology and function from the collaborative longitudinal personality disorders study.Arch Gen Psychiatry.20116882783721464343
   PubMed Web of Science ®Google Scholar
• RipollLH.TriebwasserJ.SieverU.Evidence-based pharmacotherapy for personality disorders.Int J Neuropsychopharmacol.201115132
   PubMed Web of Science ®Google Scholar
• AbrahamPF.CalabreseJR.Evidence-based pharmacologic treatment of borderline personality disorder: a shift from SSRIs to anticonvulsants and atypical antipsychotics?J Affect Disord.2008111213018304647
   PubMed Web of Science ®Google Scholar
• BellinoS.RinaldiC.BozzatelloC.BogettoF.Pharmacotherapy of borderline personality disorders systematic review for publication purpose.Curr Med Chem.2011183322322921728970
   PubMed Web of Science ®Google Scholar
• IngenhovenT.LafayP.RinneT.PasschierJ.DuivenvoordenH.Effectiveness of pharmacotherapy for severe personality disorders: metaanalyses of randomized controlled trials.J Clin Psychiatry.201071142519778496
   PubMed Web of Science ®Google Scholar
• LiebK.VollmB.RuckerG.TimmerA.StaffersJM.Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials.Br J Psychiatry.201019641220044651
   PubMed Web of Science ®Google Scholar
• MercerD.DouglassAB.LinksPS.Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms.J Personal Disord.200923156174
   PubMed Web of Science ®Google Scholar
• SaundersEF.SilkKR.Personality trait dimensions and the pharmacological treatment of borderline personality disorder.J Clin Psychopharmacol.20092946146719745646
   PubMed Web of Science ®Google Scholar
• StaffersJ.VollmBA.RuckerG.TimmerA.HubandN.LiebK.Pharmacological interventions for borderline personality disorder.Cochrane Database SystRev.20106CD005653
   Google Scholar
• FrankenburgFR.ZanariniMC.Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study.J Clin Psychiatry.20026344244612019669
   PubMed Web of Science ®Google Scholar
• ZanariniMC.FrankenburgFR.Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study.J Clin Psychiatry.20016284985411775043
   PubMed Web of Science ®Google Scholar
• SalzmanC.WolfsonAN.SchatzbergA.et alEffects of fluoxetine on anger in symptomatic volunteers with borderline personality disorder.J Clin Psychopharmacol.19951523297714224
   PubMed Web of Science ®Google Scholar
• RifkinA.QuitkinF.CarrilloC.BlumbergAG.KleinDF.Lithium carbonate in emotionally unstable character disorder.Arch Gen Psychiatry.1972275195234561258
   PubMed Web of Science ®Google Scholar
• BattagliaJ.WolffTK.Wagner-JohnsonDS.RushAJ.CarmodyTJ.BascoMR.Structured diagnostic assessment and depot f luphenazine treatment of multiple suicide attempters in the emergency department.Int Clin Psychopharmacol.19991436137210565804
   PubMed Web of Science ®Google Scholar
• CoccaroEF.KavoussiRJ.Fluoxetine and impulsive aggressive behavior in personality-disordered subjects.Arch Gen Psychiatry.199754108110889400343
   PubMed Web of Science ®Google Scholar
• GoldbergSC.SchulzSC.SchulzPM.ResnickRJ.HamerRM.FriedelRO.Borderline and schizotypal personality disorders treated with low-dose thiothixene vs. placebo.Arch Gen Psychiatry.1986436806863521531
   PubMed Web of Science ®Google Scholar
• MontgomerySA.RoyD.MontgomeryDB.The prevention of recurrent suicidal acts.Br J Clin Pharmacol.198315183S188S6824553
   PubMed Web of Science ®Google Scholar
• SerbanG.SiegelS.Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol.Am J Psychiatry.1984141145514586388363
   PubMed Web of Science ®Google Scholar
• SoloffPH.GeorgeA.NathanRS.et alProgress in pharmacotherapy of borderline disorders.Arch Gen Psychiatry.1986436916973521532
   PubMed Web of Science ®Google Scholar
• VerkesRJ.van der MastRC.HengeveldMW.TuylJP.ZwindermanAH.Van KempenGM.Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression.Am J Psychiatry.19981555435479546002
   PubMed Web of Science ®Google Scholar
• TrittK.NickelC.LahmannC.et alLamotrigine treatment of aggression in female borderline patients: a randomized, double-blind, placebocontrolled study.J Psychopharmacol.20051928729115888514
   PubMed Web of Science ®Google Scholar
• ZanariniMC.FrankenburgFR.Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study.Am J Psychiatry.200316016716912505817
   PubMed Web of Science ®Google Scholar
• ZanariniMC.FrankenburgFR.ParachiniEA.A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder.J Clin Psychiatry.2004790390715291677
   PubMedGoogle Scholar
• BogenschutzMP.NurnbergPH.Olanzapine versus placebo in the treatment of borderline personality disorder.J Clin Psychiatry.20046510410914744178
   PubMed Web of Science ®Google Scholar
• TyrerP.SilkKR.A comparison of UK and US guidelines for drug treatment in borderline personality disorder,int Rev Psychiatry.20112338839422026496
   PubMed Web of Science ®Google Scholar
• JarianiM.SaakiM.NazariH.BirjandiM.The effect of olanzapine and sertraline on personality disorder in patients with methadone maintenance therapy.Psychiatr Danub.20102254454721169896
   PubMed Web of Science ®Google Scholar
• ShaftiSS.ShahveisiB.Olanzapine versus haloperidol in the management of borderline personality disorders randomized double-blind trial.J Clin Psychopharmacol.201030444720075647
   PubMed Web of Science ®Google Scholar
• BellinoS.ParadisoE.BozzatelloP.BogettoF.Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorders pilot study.J Psychopharmacol.20102433333918719047
   PubMed Web of Science ®Google Scholar
• AdityanjeeRomineA.BrownE.ThurasP.LeeS.SchulzSC.Quetiapine in patients with borderline personality disorder: an open-label trial.Ann Clin Psychiatry.20082021922619034754
   PubMed Web of Science ®Google Scholar
• BellinoS.ParadisoE.BogettoF.Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study.J Clin Psychiatry.2006671042104616889446
   PubMed Web of Science ®Google Scholar
• Van den EyndeF.SenturkV.NaudtsK.et alEfficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder.J Clin Psychopharmacol.20082814715518344724
   PubMed Web of Science ®Google Scholar
• VilleneuveE.LemelinS.Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target.J Clin Psychiatry.2005661298130316259544
   PubMed Web of Science ®Google Scholar
• BellinoS.ParadisoE.BogettoF.Oxcarbazepine in the treatment of borderline personality disorder: a pilot study.J Clin Psychiatry.2005661111111516187767
   PubMed Web of Science ®Google Scholar
• MiyaokaT.FuruyaM.YasudaH.HayashiaM.InagakiT.HoriguchiJ.Yigan san for the treatment of borderline personality disorder: an open-label study.Prog Neuropsychopharmacol Biol Psychiatry.20083215015417765378
   PubMed Web of Science ®Google Scholar
• HesseE.The Adult Attachment lnterview:Protocol, method of analysis, and empirical studies. In: Hesse E, ed.Handbook of Attachment, Second Edition: Theory, Research, and Clinical Applications. New York, NY:Guilford Press;2008552598
   Google Scholar
• AgrawalHR.GundersonJ.HolmesBM.Lyons-RuthK.Attachment studies with borderline patients: a review.Harv Rev Psychiatry.2004129410415204804
   PubMed Web of Science ®Google Scholar
• CoccaroEF.KavoussiRJ.HaugerRL.Physiological responses to d-fenfluramine and ipsapirone challenge correlate with indices of aggression in males with personality disorder.Int Clin Psychopharmacol.1995101771798675971
   PubMed Web of Science ®Google Scholar
• CoccaroEF.SieverLJ.KlarHM.MaurerG.et alSerotonergic studies in patients with affective and personality disordersxorrelates with suicidal and impulsive aggressive behavior.Arch Gen Psychiatry.1989465875992735812
   PubMed Web of Science ®Google Scholar
• EvendenJ.Impulsivity: a discussion of clinical and experimental findings.J Psychopharmacol.19991318019210475725
   PubMed Web of Science ®Google Scholar
• MaloneKM.CorbittEM.LiS.MannJJ.Prolactin response to fenfluramine and suicide attempt lethality in major depression.Br J Psychiatry.19961683243298833686
   PubMed Web of Science ®Google Scholar
• NewAS.GoodmanM.TriebwasserJ.SieverLJ.Recent advances in the biological study of personality disorders.Psychiatr Clin North Am.20083144146118638645
   PubMed Web of Science ®Google Scholar
• NewAS.HazlettEA.BuchsbaumMS.et alBlunted prefrontal cortical 18fluorodeoxyglucose positron emission tomography response to metachlorophenylpiperazine in impulsive aggression.Arch Gen Psychiatry.20025962162912090815
   PubMed Web of Science ®Google Scholar
• NewAS.TrestmanR.MitropoulouV.et alLow prolactin response to fenfluramine in impulsive aggression.J Psychiatr Res.20043822323015003426
   PubMed Web of Science ®Google Scholar
• NewAS.TrestmanR.MitropoulouV.et alSerotonergic function and self-injurious behavior in personality disorder patients.Psychiatry Res.19976917269080541
   PubMed Web of Science ®Google Scholar
• OquendoMA.KrunicA.ParseyRV.et alPositron emission tomography of regional brain metabolic responses to a serotonergic challenge in major depressive disorder with and without borderline personality disorder.Neuropsychopharmacology.2005301163117215770239
   PubMed Web of Science ®Google Scholar
• PitchotW.HansenneM.PintoE.ReggersJ.FuchsS.AnsseauM.5-Hydroxytryptamine 1A receptors, major depression, and suicidal behavior.Biol Psychiatry.2005588545816139805
   PubMed Web of Science ®Google Scholar
• SamuelssonM.JokinenJ.NordstromAL.NordstromP.CSF 5-HIAA, suicide intent and hopelessness in the prediction of early suicide in male highrisk suicide attempters.Acta Psychiatr Scand.2006113444716390368
   PubMed Web of Science ®Google Scholar
• SieverLJ.BuchsbaumMS.NewAS.et alD,L-fenfluramine response in impulsive personality disorder assessed with [18F]fluorodeoxyglucose positron emission tomography.Neuropsychopharmacology.19992041342310192822
   PubMed Web of Science ®Google Scholar
• SilvaH.IturraP.SolariA.et alSerotonin transporter polymorphism and fluoxetine effect on impulsiveness and aggression in borderline personality disorder.Actas Esp Psiquiatr.20073538739217597424
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association Practice guideline. Practice guideline for the treatment of patients with borderline personality disorder. American Psychiatric Association.Am J Psychiatry.2001158(10 suppl)152
   Web of Science ®Google Scholar
• RinneT.van den BrinkW.WoutersL.van DyckR.SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder.Am J Psychiatry.20021592048205412450955
   PubMed Web of Science ®Google Scholar
• SoloffPH.GeorgeA.NathanRS.SchulzPM.UlrichRF.PerelJM.Amitryptiline and haloperidol in unstable and schizotypal borderline disorders.Psychopharmacol Bull.1986221771823523575
   PubMedGoogle Scholar
• SoloffPH.GeorgeA.NathanRS.SchulzPM.PerelJM.Behavioral dyscontrol in borderline patients treated with amitryptiline.Psychopharmacol Bull.1987231771813602316
   PubMedGoogle Scholar
• SoloffPH.GeorgeA.NathanRS.SchulzPM.PerelJM.Paradoxical effects of amitryptiline on borderline patients.Am J Psychiatry.1986143160316053538914
   PubMed Web of Science ®Google Scholar
• AydukO.ZayasV.DowneyG.ColeAB.ShodaY.MischelW.Rejection sensitivity and executive controfjoint predictors of borderline personality features.J Res Pers.20084215116818496604
   PubMed Web of Science ®Google Scholar
• StaeblerK.HelbingE.RosenbachC.RennebergB.Rejection sensitivity and borderline personality disorder.Clin Psychol Psychother.20111827528321110407
   PubMed Web of Science ®Google Scholar
• CorneliusJR.SoloffPH.PerelJM.UlrichRF.Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine.Am J Psychiatry.1993150184318488238640
   PubMed Web of Science ®Google Scholar
• CowdryRW.GardnerDL.Pharmacotherapy of borderline personality disorderslprazolam, carbamazepine, trifluoperazine, and tranylcypromine.Arch Gen Psychiatry.1988451111193276280
   PubMed Web of Science ®Google Scholar
• ParsonsB.QuitkinFM.McGrathPJ.et alPhenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression.Psychopharmacol Bull.1989255245342698483
   PubMedGoogle Scholar
• SoloffPH.CorneliusJ.GeorgeA.NathanS.PerelJM.UlrichRF.Efficacy of phenelzine and haloperidol in borderline personality disorder.Arch Gen Psychiatry.1993503773858489326
   PubMed Web of Science ®Google Scholar
• HazlettEA.ZhangJ.NewAS.et alPotentiated amygdala response to repeated emotional pictures in borderline personality disorder.Biol Psychiatry.2012724485622560044
   PubMed Web of Science ®Google Scholar
• HigginsGA.EnderlinM.HamanM.FletcherPJ.The 5-HT2A receptor antagonist M100.907 attenuates motor and'impulsive-type' behaviours produced by NMDA receptor antagonism.Psychopharmacology (Berl).200317030931912904968
   PubMed Web of Science ®Google Scholar
• WinstanleyCA.TheobaldDE.DalleyJW.GlennonJC.RobbinsTW.5HT2A and 5-HT2C receptor antagonists have opposing effects on a measure of impulsivity: interactions with global 5-HT depletion.Psychopharmacology (Berl).200417637638515232674
   PubMed Web of Science ®Google Scholar
• HombergJR.Serotonin and decision-making processes.Neurosci BiobehavRev.201236218236
   PubMed Web of Science ®Google Scholar
• TakahashiA.QuadrosIM.de AlmeidaRM.MiczekKA.Behavioral and pharmacogenetics of aggressive behavior.Curr Top Behav Neurosci.20121273138
   PubMedGoogle Scholar
• AssadiSM.YucelM.PantelisC.Dopamine modulates neural networks involved in effort-based decision-making.Neurosci Biobehav Rev.20093338339319046987
   PubMed Web of Science ®Google Scholar
• NickelMK.LoewTH.Pedrosa GilF.Aripiprazole in treatment of borderline patients, part ll:an 18-month follow-up.Psychopharmacology.20071911023102617318503
   PubMed Web of Science ®Google Scholar
• NickelMK.MuehlbacherM.NickelC.et alAripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study.Am J Psychiatry.200616383383816648324
   PubMed Web of Science ®Google Scholar
• LinehanMM.McDavidJD.BrownMZ.SayrsJH.GallopRJ.Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorders double-blind, placebo-controlled pilot study.J Clin Psychiatry.200869999100518466045
   PubMed Web of Science ®Google Scholar
• SolerJ.PascualJC.CampinsJ.et alDouble-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder.Am J Psychiatry.20051621221122415930077
   PubMed Web of Science ®Google Scholar
• SchulzSC.ZanariniMC.BatemanA.et alOlanzapine for the treatment of borderline personality disordervariable dose 12 week randomised double-blind placebo-controlled study.Br J Psychiatry.200819348549219043153
   PubMed Web of Science ®Google Scholar
• ZanariniMC.SchulzSC.DetkeHC.et alA dose comparison of olanzapine for the treatment of borderline personality disorder: a 12 week randomized, double-blind, placebo-controlled study.J Clin Psychiatry.2011721353136221535995
   PubMed Web of Science ®Google Scholar
• ZanariniMC.SchulzSC.DetkeHC.et alOpen-label treatment with olanzapine for patients with borderline personality disorder.J Clin Psychopharmacol.20123239840222544004
   PubMed Web of Science ®Google Scholar
• PascualJC.SolerJ.PuigdemontD.et alZiprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study.J Clin Psychiatry.20086960360818251623
   PubMed Web of Science ®Google Scholar
• ZanariniMC.ReichmanCA.FrankenburgFR.ReichDB.FitzmauriceG.The course of eating disorders in patients with borderline personality disorder: a 10-year follow-up study.Int J Eat Disord.20104322623219343799
   PubMed Web of Science ®Google Scholar
• FrankenburgFR.ZanariniMC.Obesity and obesity-related illnesses in borderline patients.J Personal Disord.2006207180
   PubMed Web of Science ®Google Scholar
• BoltonS.GundersonJG.Distinguishing borderline personality disorder from bipolar disorder: differential diagnosis and implications.Am J Psychiatry.1996153120212078780426
   PubMed Web of Science ®Google Scholar
• CritchfieldKL.LevyKN.ClarkinJF.KernbergOF.The relational context of aggression in borderline personality disordenusing adult attachment style to predict forms of hostility.J Clin Psychol.200864678218161033
   PubMed Web of Science ®Google Scholar
• GundersonJG.Disturbed relationships as a phenotype for borderline personality disorder.Am J Psychiatry.20071641637164017974925
   PubMed Web of Science ®Google Scholar
• HenryC.MitropoulouV.NewAS.KoenigsbergHW.SilvermanJ.SieverLJ.Affective instability and impulsivity in borderline personality and bipolar II disorders: similarities and differences.J Psychiatr Res.20013530731211684137
   PubMed Web of Science ®Google Scholar
• ParisJ.Borderline or bipolar? Distinguishing borderline personality disorder from bipolar spectrum disorders.Harv Rev Psychiatry.20041214014515371068
   PubMed Web of Science ®Google Scholar
• LinksPS.SteinerM.BoiagoI.IrwinD.Lithium therapy for borderline patients:preliminary findings.J Personal Disord.19904173181
   Google Scholar
• GardnerDL.CowdryRW.Development of melancholia during carbamazepine treatment in borderline personality disorder.J Clin Psychopharmacol.198662362393525615
   PubMed Web of Science ®Google Scholar
• GardnerDL.CowdryRW.Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder.Am J Psychiatry.19861435195223513634
   PubMed Web of Science ®Google Scholar
• de la FuenteJM.LotstraF.Atrial of carbamazepine in borderline personality disorder.Eur Neuropsychopharmacol.199444794867894258
   PubMed Web of Science ®Google Scholar
• LoewTH.NickelMK.MuehlbacherM.et alTopiramate treatment of women with borderline personality disorder: a double-blind, placebo-controlled study.J Clin Psychopharmacol.200626616616415708
   PubMed Web of Science ®Google Scholar
• LoewTH.NickelMK.Topiramate treatment of women with borderline personality disorder, part ll:an open 18-month follow-up.J Clin Psychopharmacol.20082835535718480701
   PubMed Web of Science ®Google Scholar
• NickelMK.LoewTH.Treatment of aggression with topiramate in male borderline patients, part II: 18-month follow-up.Eur Psychiatry.20082311511718024088
   PubMed Web of Science ®Google Scholar
• NickelMK.NickelC.KaplanP.et alTreatment of aggression with topiramate in male borderline patients:a double-blind, placebo-controlled study.Biol Psychiatry.20055749549915737664
   PubMed Web of Science ®Google Scholar
• NickelMK.NickelC.MitterlehnerFO.et alTopiramate treatment of aggression in female borderline personality disorder patients: a doubleblind, placebo-controlled study.J Clin Psychiatry.2004651515151915554765
   PubMed Web of Science ®Google Scholar
• ReichDB.ZanariniMC.BieriKA.A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder.Int Clin Psychopharmacol.20092427027519636254
   PubMed Web of Science ®Google Scholar
• LeiberichF.NickelMK.TrittK.Pedrosa GilF.Lamotrigine treatment of aggression in female borderline patients, part II: an 18-month follow-up. JPsychopharmacol.2008805808
   Web of Science ®Google Scholar
• HollanderE.SwannAC.CoccaroEF.et alImpact of trait impulsivity and state aggression on divalproex vs. placebo response in borderline personality disorder.Am J Psychiatry.200516262162415741486
   PubMed Web of Science ®Google Scholar
• ZiegenhornAA.RoepkeS.SchommerNC.et alClonidine improves hyperarousal in borderline personality disorder with or without comorbid post-traumatic stress disorders randomized, double-blind, placebo-controlled trial.J Clin Psychopharmacol.20092917017319512980
   PubMed Web of Science ®Google Scholar
• BandelowB.SchmahlC.FalkaiP.WedekindD.Borderline personality disorders dysregulation of the endogenous opioid system?Psychol Rev.201011762363620438240
   PubMed Web of Science ®Google Scholar
• StanleyB.SieverLJ.The interpersonal dimension of borderline personality disorder: toward a neuropeptide model.Am J Psychiatry.2010167243919952075
   PubMed Web of Science ®Google Scholar
• DepueRA.Morrone-StrupinskyJV.A neurobehavioral model of aff illative bonding: implications for conceptualizing a human trait of affiliation.Behav Brain Sci.20052831339516209725
   PubMed Web of Science ®Google Scholar
• HighamJP.BarrCS.HoffmanCL.MandalaywalaTM.ParkerKJ.MaestripieriD.Mu opioid receptor variation, oxytocin levels, and maternal attachment in free-ranging rhesus macaques Macaca mulatta.Behav Neurosci.201112513113621463018
   PubMed Web of Science ®Google Scholar
• TroisiA.FrazzettoG.CarolaV.et alVariation in the -opioid receptor gene (OPRM1 ) moderates the influence of early maternal care on fearful attachment. SocCogn Affect Neurosci.20127542547
   PubMed Web of Science ®Google Scholar
• ProssinAR.LoveTM.KoeppeRA.ZubietaJK.SilkKR.Dysregulation of regional endogenous opioid function in borderline personality disorder.Am J Psychiatry.201016792593320439388
   PubMed Web of Science ®Google Scholar
• BohusMJ.LandwehrmeyerGB.StiglmayrCE.LimbergerMF.BohmeR.SchmahlCG.Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disordersn open-label trial.J Clin Psychiatry.19996059860310520978
   PubMed Web of Science ®Google Scholar
• Ebner-PriemerUW.MauchnikJ.KleindienstN.et alEmotional learning during dissociative states in borderline personality disorder.J Psychiatry Neurosci.2009342142219448852
   PubMed Web of Science ®Google Scholar
• SaperJR.Borderline personality, opioids, and naltrexone.Headache.20004076576611091301
   PubMed Web of Science ®Google Scholar
• ThuraufNJ.WasheimHA.The effects of exogenous analgesia in a patient with borderline personality disorder (BPD) and severe self-injurious behavior.Eur J Pain.2000410710910833560
   PubMed Web of Science ®Google Scholar
• PhilipsenA.SchmahlC.LiebK.Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder.Pharmacopsychiatry.20043719619915470797
   PubMed Web of Science ®Google Scholar
• SchmahlC.KleindienstN.LimbergerM.et alEvaluation of naltrexone for dissociative symptoms in borderline personality disorder,int Clin Psychopharmacol.201227616822002175
   PubMed Web of Science ®Google Scholar
• BartzJA.ZakiJ.BolgerN.OchsnerKN.Social effects of oxytocin in humans: context and person matter.Trends Cogn Sci.20111530130921696997
   PubMed Web of Science ®Google Scholar
• De DreuCKW.GreerLL.Van KleefGA.ShalviS.HandgraafMJ.Oxytocin promotes human ethnocentrism .Proc Natl Acad Sci USA.20111081262126621220339
   PubMed Web of Science ®Google Scholar
• FeldmanR.WellerA.Zagoory-SharonO.LevineA.Evidence for a neuroendocrinological foundation of human affiliation: plasma oxytocin levels across pregnancy and the postpartum period predict mother-infant bonding.Psychol Sci.20071896597017958710
   PubMed Web of Science ®Google Scholar
• BartzJ.SimeonD.HamiltonH.et alOxytocin can hinder trust and cooperation in borderline personality disorder.Soc Cogn Affect Neurosci.2011655656321115541
   PubMed Web of Science ®Google Scholar
• SimeonD.BartzJ.HamiltonH.et alOxytocin administration attenuates stress reactivity in borderline personality disorder: a pilot study.Psychoneuroendocrinology.20113614181421 21546164
   PubMed Web of Science ®Google Scholar
• SimpsonEB.YenS.CostelloE.et alCombined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder.J Clin Psychiatry.20046537938515096078
   PubMed Web of Science ®Google Scholar
• GrosjeanB.TsaiGE.NMDA neurotransmission as a critical mediator of borderline personality disorder.J Psychiatry Neurosci.20073210311517353939
   PubMed Web of Science ®Google Scholar
• DiergaardeL.SchoffelmeerAN.De VriesTJ.Pharmacological manipulation of memory consolidation: towards a novel treatment of pathogenic memories.Eur J Pharmacol.200858545345718410917
   PubMed Web of Science ®Google Scholar
• StecklerT.RisbroughV.Pharmacological treatment of PTSD—established and new approaches.Neuropharmacology.20126261762721736888
   PubMed Web of Science ®Google Scholar
• PattijT.VanderschurenLJ.The neuropharmacology of impulsive behaviour.Trends Pharmacol Sci.20082919219918304658
   PubMed Web of Science ®Google Scholar
• VinodKY.HungundBL.Role of the endocannabinoid system in depression and suicide.Trends Pharmacol Sci.20062753954516919786
   PubMed Web of Science ®Google Scholar
• ParolaroD.RealiniN.ViganoD.GuidaliC.RubinoT.The endocannabinoid system and psychiatric disorders.Exp Neurol.201022431420353783
   PubMed Web of Science ®Google Scholar
• FitzgeraldML.ShobinE.PickelVM.Cannabinoid modulation of the dopaminergic circuitry:implications for limbic and striatal output.Prog Neuropsychopharmacol Biol Psychiatry.201238212922265889
   PubMed Web of Science ®Google Scholar
• de BitencourtRM.PamplonaFA.TakahashiRN.A current overview of cannabinoids and glucocorticoids in facilitating extinction of aversive memories:potential extinction enhancers.Neuropharmacology.20136438939522687521
   PubMed Web of Science ®Google Scholar
• KnollAT.CarlezonWA Jr.Dynorphin, stress, and depression.Brain Res.20101314567319782055
   PubMed Web of Science ®Google Scholar
• CarrGV.BangasserDA.BetheaT.YoungM.ValentinoRJ.LuckiI.Antidepressant-like effects of kappa opioid receptor antagonists in Wistar Kyoto rats.Neuropsychopharmacology.20103575276319924112
   PubMed Web of Science ®Google Scholar
• ChartoffE.SawyerA.RachlinA.PotterD.PliakasA.CarlezonWA.Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats.Neuropharmacology.2012621677621736885
   PubMed Web of Science ®Google Scholar
• PetersMF.ZaccoA.GordonJ.et alIdentification of short-acting K-opioid antagonists with anxiolytic-like activity.Eur J Pharmacol.2011661273421539838
   PubMed Web of Science ®Google Scholar